Cost-Effectiveness Analysis of Aztreonam–Avibactam Compared with Colistin Plus Meropenem in Treating Metallo-Beta-Lactamase-Producing Enterobacterales Infections in Spain
ATM-AVI is a highly cost-effective antibiotic versus COL+MER in the management of patients with serious infections caused by MBL-Enterobacterales.
Authors
- Leonor Periañez Parraga (ORCID: https://orcid.org/0000-0002-9274-5100)
- Alfonso De Lossada Juste
- Patricia Ruíz-Garbajosa (ORCID: https://orcid.org/0000-0003-4795-0217)
- Carlota Moya-Alarcón (ORCID: https://orcid.org/0000-0003-4873-7362)
- Julián Torre‐Cisneros (ORCID: https://orcid.org/0000-0003-1529-6302)
- Maria Gheorghe (ORCID: https://orcid.org/0000-0002-4128-6063)
- Gerardo Aguilar (ORCID: https://orcid.org/0000-0001-7997-4294)
- Marta Maroto-Díaz
- María del Carmen de Ceano-Vivas
- Sara Arranz Gonzalo
- Alba Villacampa Lordan (ORCID: https://orcid.org/0009-0009-0152-6294)
Institutions
- Pfizer (United States) (US)
- Instituto Cajal (ES)
- Instituto de Salud Carlos III (ES)
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Light Prescriptions Innovators (Spain) (ES)
- Hospital Universitario Reina Sofía (ES)
- Pfizer (Spain) (ES)
- Hospital Universitario Son Espases (ES)
- INCLIVA Health Research Institute (ES)
- Medical Research Network (US)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1007/s40121-025-01257-5
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00